Moderna reports surprise profit on higher-than-expected COVID vaccine sales
Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...
Moderna Stock Gains on Better-Than-Expected Covid-19 Vaccine Sales
Moderna shares jumped after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed ...
Canada approves Moderna's RSV vaccine for adults aged 60 and older
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
Inside Moderna’s Tech-Driven Culture: Insights From CIO Brad Miller
Brad Miller, Moderna's CIO, has driven technology innovation to help drive continued gains for the roughly $7 billion revenue ...
FiercePharma6d
Moderna disappoints in RSV debut, squares up with Pfizer in COVID-19 vaccine sales
Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...
How Moderna used niche influencers to drive vaccinations despite COVID fatigue
Coegi used more than 500 million impressions and paid social optimized with attention and emotion metrics to drive 24% of ...
Moderna sales get lift from early nod for newest COVID shot
The Cambridge-based company’s latest COVID shot was approved three weeks earlier than last year, according to a statement ...
Canada approves Moderna's RSV vaccine for those age 60 and older, company says
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
BioPharma Dive5d
Moderna earnings beat forecasts, but analysts question whether sales spike will last
Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.
Cautious Outlook on Moderna: Declining Vaccine Demand and Strategic Challenges Prompt Sell Rating
Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...
Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand Slowdown And Market Share Concerns, Analysts Warn
Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...
CNBC on MSN6d
Moderna posts surprise profit as Covid vaccine sales impress, cost cuts take hold
Moderna said its newest Covid vaccine saw benefits after winning approval in the U.S. three weeks earlier than the last iteration of the shot did in 2023.